ALTACCO

Altacco is a clinical-stage biotechnology company based in Baar, Switzerland, dedicated to advancing the field of Targeted Alpha Therapy (TAT) for cancer treatment. The company focuses on the development of innovative radiopharmaceuticals utilizing Lead-212 (212Pb), a powerful alpha-emitting isotope known for its high linear energy transfer and short range, which allows for precise destruction of tumor cells. Altacco's lead clinical program, ALT-001, targets somatostatin receptors in patients with neuroendocrine tumors, aiming to provide a more potent alternative to existing beta-emitting therapies. The company's pipeline also includes ALT-002, a TAT candidate targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic prostate cancer. Founded by industry veterans with extensive experience in radiopharmaceutical development, Altacco leverages proprietary chelator and linker technologies to optimize the stability and efficacy of its therapeutic candidates.